Royal Bank of Canada’s ProQR Therapeutics PRQR Stock Holding History

Royal Bank of Canada’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Sell	308 -9,995	-97%	-$16.4K	﹤0.01%	7559
2025 Q4	$20K	Sell	10,303 -81,904	-89%	-$191K	﹤0.01%	6049
2025 Q3	$196K	Sell	92,207 -20,193	-18%	-$44.1K	﹤0.01%	5100
2025 Q2	$229K	Buy	112,400 +112,200	+56,100%	+$183K	﹤0.01%	5060
2025 Q1	$0	Hold	200	–	–	﹤0.01%	7151
2024 Q4	$1K	Hold	200	–	–	﹤0.01%	6814
2024 Q3	$0	Sell	200 -855	-81%	-$1.6K	﹤0.01%	7305
2024 Q2	$2K	Buy	1,055 +855	+428%	+$1.66K	﹤0.01%	6746
2024 Q1	$0	Hold	200	–	–	﹤0.01%	7468
2023 Q4	$0	Hold	200	–	–	﹤0.01%	7478
2023 Q3	$0	Hold	200	–	–	﹤0.01%	7456
2023 Q2	$0	Hold	200	–	–	﹤0.01%	7563
2023 Q1	$0	Hold	200	–	–	﹤0.01%	7385
2022 Q4	$1K	Hold	200	–	–	﹤0.01%	7067
2022 Q3	$0	Hold	200	–	–	﹤0.01%	7762
2022 Q2	$0	Sell	200 -56,073	-100%	-$41.8K	﹤0.01%	7639
2022 Q1	$51K	Hold	56,273	–	–	﹤0.01%	6082
2021 Q4	$451K	Sell	56,273 -2,000	-3%	-$15.2K	﹤0.01%	4561
2021 Q3	$488K	Buy	58,273 +3,000	+5%	+$19.6K	﹤0.01%	4379
2021 Q2	$372K	Buy	55,273 +665	+1%	+$4.29K	﹤0.01%	4529
2021 Q1	$361K	Buy	54,608 +2,000	+4%	+$10.2K	﹤0.01%	4451
2020 Q4	$221K	Sell	52,608 -550	-1%	-$2.32K	﹤0.01%	4789
2020 Q3	$255K	Sell	53,158 -11,500	-18%	-$60.1K	﹤0.01%	4369
2020 Q2	$393K	Buy	64,658 +49,256	+320%	+$266K	﹤0.01%	3966
2020 Q1	$85K	Buy	15,402 +13,656	+782%	+$105K	﹤0.01%	4871
2019 Q4	$17K	Buy	1,746 +996	+133%	+$7.76K	﹤0.01%	5929
2019 Q3	$4K	Buy	750 +550	+275%	+$4.39K	﹤0.01%	6110
2019 Q2	$2K	Hold	200	–	–	﹤0.01%	6592
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	6438
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	6348
2018 Q3	$4K	Hold	200	–	–	﹤0.01%	6351
2018 Q2	$1K	Sell	200 -523	-72%	-$2.64K	﹤0.01%	6378
2018 Q1	$3K	Hold	723	–	–	﹤0.01%	6056
2017 Q4	$3K	Hold	723	–	–	﹤0.01%	6206
2017 Q3	$4K	Buy	723 +200	+38%	+$1.04K	﹤0.01%	6467
2017 Q2	$3K	Hold	523	–	–	﹤0.01%	6200
2017 Q1	$3K	Hold	523	–	–	﹤0.01%	6360
2016 Q4	$3K	Hold	523	–	–	﹤0.01%	6420
2016 Q3	$3K	Hold	523	–	–	﹤0.01%	6101
2016 Q2	$3K	Sell	523 -2,000	-79%	-$10.3K	﹤0.01%	6070
2016 Q1	$13K	Buy	2,523 +2,000	+382%	+$10.2K	﹤0.01%	5649
2015 Q4	$5K	Hold	523	–	–	﹤0.01%	6161
2015 Q3	$8K	Hold	523	–	–	﹤0.01%	5990
2015 Q2	$9K	Sell	523 -1	-0.2%	-$19	﹤0.01%	6092
2015 Q1	$11K	Buy	+524	New	+$10.8K	﹤0.01%	5548

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Royal Bank of Canada's PRQR Position: Q1 2026 in Review

Royal Bank of Canada reduced its ProQR Therapeutics (PRQR) stake by 97% in Q1 2026, selling an estimated $16.4K and leaving 308 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7559.

Royal Bank of Canada first reported a position in PRQR in Q1 2015 and has held it in 45 quarters since. The position peaked at $488K in Q3 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Royal Bank of Canada held 308 shares of ProQR Therapeutics worth $0 as of Q1 2026.
Royal Bank of Canada sold 9,995 ProQR Therapeutics shares in Q1 2026, an estimated $16.4K.
ProQR Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7559 holding.
Royal Bank of Canada first reported a position in ProQR Therapeutics in Q1 2015 and has held it in 45 quarters since.
Royal Bank of Canada's ProQR Therapeutics position peaked at $488K in Q3 2021.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.